Investigation of efficacy and safety of insulin degludec or insulin glargine in type 2 diabetes with basal-bolus therapy

Investigation of efficacy and safety of insulin degludec or insulin glargine in type 2 diabetes with basal-bolus therapy - JUN-SIBA study:Juntendo-Soluble Insulin Basal Analogue study 4

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013872

Enrollment

Registered

2014-05-07

Start date

2014-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Conventional group: to adjust the amount of insulin glargine according to the algorithm Change group: to perform switching in the same unit to insulin degludec from insulin glargine, to adjust the amo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Fasting blood glucose is inadequately-controlled patients at 140 mg/dl or more 2)Patients who have done more than 6 months Basal-Bolus Therapy 3)BMI less than 35kg/m2

Exclusion criteria

Exclusion criteria: 1)hypersensitivity to degludec 2)patient with hypoglycemia 3)patient with serious liver and kidney disease 4)patient with proliferative retinopathy 5)during pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
1. MAGE and MODD by CGM 2. nocturnal hypoglycemia frequency	—

Countries

Japan

Contacts

Public ContactFuki Ikeda

Juntendo University Graduate School of Medicine Department of Metabolism & Endocrinology

fuki@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026